[DEF 14A] Nathan's Famous Inc Definitive Proxy Statement
Intellia Therapeutics, Inc. (NTLA) – Form 4 insider filing
EVP & CFO Edward J. Dulac III executed an automatic, non-volitional sale of 7,462 common shares on 23 Jul 2025 at $14.02 per share. The disposition was a mandatory “sell-to-cover” to satisfy federal and state tax-withholding obligations triggered by the vesting of RSUs on 22 Jul 2025.
Post-transaction, Dulac directly owns 106,062 NTLA shares; no indirect holdings or derivative security changes were reported. No options were exercised or granted, and the filing does not disclose any additional share sales or purchases.
The event does not materially alter management’s economic exposure to the company and should be viewed as administrative rather than discretionary trading activity.
Intellia Therapeutics, Inc. (NTLA) – Comunicazione interna Form 4
Il EVP e CFO Edward J. Dulac III ha effettuato una vendita automatica e non volontaria di 7.462 azioni ordinarie il 23 luglio 2025 al prezzo di 14,02 $ per azione. Questa cessione è stata una vendita obbligatoria “sell-to-cover” per adempiere agli obblighi di ritenuta fiscale federale e statale derivanti dalla maturazione delle RSU il 22 luglio 2025.
Dopo la transazione, Dulac detiene direttamente 106.062 azioni NTLA; non sono stati segnalati possedimenti indiretti o modifiche a strumenti derivati. Non sono state esercitate o concesse opzioni, e la comunicazione non riporta ulteriori vendite o acquisti di azioni.
L’evento non modifica sostanzialmente l’esposizione economica del management verso la società e va considerato un’operazione amministrativa piuttosto che una decisione di trading discrezionale.
Intellia Therapeutics, Inc. (NTLA) – Presentación interna Formulario 4
El EVP y CFO Edward J. Dulac III realizó una venta automática y no voluntaria de 7,462 acciones comunes el 23 de julio de 2025 a $14.02 por acción. La disposición fue una venta obligatoria “sell-to-cover” para cumplir con las obligaciones de retención fiscal federales y estatales derivadas de la consolidación de las RSU el 22 de julio de 2025.
Después de la transacción, Dulac posee directamente 106,062 acciones NTLA; no se reportaron tenencias indirectas ni cambios en valores derivados. No se ejercieron ni otorgaron opciones, y la presentación no revela ventas o compras adicionales de acciones.
El evento no altera materialmente la exposición económica de la gerencia a la empresa y debe considerarse como una actividad administrativa más que una operación discrecional de trading.
Intellia Therapeutics, Inc. (NTLA) – 내부자 신고서 Form 4
EVP 겸 CFO Edward J. Dulac III는 2025년 7월 23일에 주당 $14.02에 7,462주의 보통주를 자동적이고 비자발적으로 매도했습니다. 이 처분은 2025년 7월 22일 RSU 권리 확정에 따른 연방 및 주 세금 원천징수 의무를 충족하기 위한 필수 “sell-to-cover” 매도였습니다.
거래 후 Dulac는 직접적으로 106,062주 NTLA 주식을 보유하고 있으며, 간접 보유나 파생상품 변동은 보고되지 않았습니다. 옵션의 행사나 부여는 없었고, 추가적인 주식 매매도 공개되지 않았습니다.
이 사건은 경영진의 회사에 대한 경제적 노출에 실질적인 변화를 주지 않으며, 자발적 거래보다는 행정적 조치로 봐야 합니다.
Intellia Therapeutics, Inc. (NTLA) – Déclaration d’initié Formulaire 4
Le EVP et CFO Edward J. Dulac III a procédé à une vente automatique et non volontaire de 7 462 actions ordinaires le 23 juillet 2025 au prix de 14,02 $ par action. Cette cession était une vente obligatoire « sell-to-cover » visant à satisfaire les obligations de retenue d’impôt fédérales et étatiques déclenchées par l’acquisition des RSU le 22 juillet 2025.
Après la transaction, Dulac détient directement 106 062 actions NTLA ; aucune détention indirecte ni modification de titres dérivés n’a été signalée. Aucune option n’a été exercée ou attribuée, et la déclaration ne révèle aucune autre vente ou achat d’actions.
L’événement ne modifie pas de manière significative l’exposition économique de la direction à l’entreprise et doit être considéré comme une opération administrative plutôt que comme une transaction discrétionnaire.
Intellia Therapeutics, Inc. (NTLA) – Form 4 Insider-Meldung
EVP & CFO Edward J. Dulac III führte am 23. Juli 2025 einen automatischen, nicht freiwilligen Verkauf von 7.462 Stammaktien zum Preis von 14,02 $ pro Aktie durch. Die Veräußerung war ein verpflichtender „Sell-to-Cover“-Verkauf zur Erfüllung der bundesstaatlichen und staatlichen Steuerabzugsverpflichtungen, die durch die Vesting der RSUs am 22. Juli 2025 ausgelöst wurden.
Nach der Transaktion besitzt Dulac direkt 106.062 NTLA-Aktien; keine indirekten Beteiligungen oder Änderungen von Derivaten wurden gemeldet. Es wurden keine Optionen ausgeübt oder gewährt, und die Meldung enthält keine weiteren Aktienverkäufe oder -käufe.
Das Ereignis verändert die wirtschaftliche Beteiligung des Managements am Unternehmen nicht wesentlich und sollte als administrative und nicht als diskretionäre Handelsaktivität betrachtet werden.
- Executive retains 106,062 shares, indicating continued alignment with shareholder interests.
- Transaction was pre-programmed and tax-driven, reducing concerns about opportunistic insider selling.
- Even administrative insider sales can create superficial bearish headlines that may pressure short-term sentiment.
Insights
TL;DR: Routine sell-to-cover, neutral signal.
The CFO’s 7,462-share sale—only ~7% of his 106k-share stake—was required to cover taxes on vested RSUs, a common practice that avoids out-of-pocket tax payments. Because the shares were disposed automatically and promptly disclosed, the transaction offers little insight into management’s outlook on NTLA fundamentals. Insider ownership remains significant, supporting alignment with shareholders. I regard the filing as operationally neutral with no valuation impact.
TL;DR: Compliant disclosure, immaterial governance impact.
The form demonstrates timely Section 16 compliance, detailing a tax-driven sale under Rule 10b5-1-like mechanics. Such sell-to-cover transactions are typically pre-approved and avoid potential trading-window issues. Retention of over 100k shares preserves meaningful ‘skin in the game,’ and no red flags emerge regarding unusual trading patterns. Governance impact is minimal; investors should focus on broader performance catalysts rather than this single administrative filing.
Intellia Therapeutics, Inc. (NTLA) – Comunicazione interna Form 4
Il EVP e CFO Edward J. Dulac III ha effettuato una vendita automatica e non volontaria di 7.462 azioni ordinarie il 23 luglio 2025 al prezzo di 14,02 $ per azione. Questa cessione è stata una vendita obbligatoria “sell-to-cover” per adempiere agli obblighi di ritenuta fiscale federale e statale derivanti dalla maturazione delle RSU il 22 luglio 2025.
Dopo la transazione, Dulac detiene direttamente 106.062 azioni NTLA; non sono stati segnalati possedimenti indiretti o modifiche a strumenti derivati. Non sono state esercitate o concesse opzioni, e la comunicazione non riporta ulteriori vendite o acquisti di azioni.
L’evento non modifica sostanzialmente l’esposizione economica del management verso la società e va considerato un’operazione amministrativa piuttosto che una decisione di trading discrezionale.
Intellia Therapeutics, Inc. (NTLA) – Presentación interna Formulario 4
El EVP y CFO Edward J. Dulac III realizó una venta automática y no voluntaria de 7,462 acciones comunes el 23 de julio de 2025 a $14.02 por acción. La disposición fue una venta obligatoria “sell-to-cover” para cumplir con las obligaciones de retención fiscal federales y estatales derivadas de la consolidación de las RSU el 22 de julio de 2025.
Después de la transacción, Dulac posee directamente 106,062 acciones NTLA; no se reportaron tenencias indirectas ni cambios en valores derivados. No se ejercieron ni otorgaron opciones, y la presentación no revela ventas o compras adicionales de acciones.
El evento no altera materialmente la exposición económica de la gerencia a la empresa y debe considerarse como una actividad administrativa más que una operación discrecional de trading.
Intellia Therapeutics, Inc. (NTLA) – 내부자 신고서 Form 4
EVP 겸 CFO Edward J. Dulac III는 2025년 7월 23일에 주당 $14.02에 7,462주의 보통주를 자동적이고 비자발적으로 매도했습니다. 이 처분은 2025년 7월 22일 RSU 권리 확정에 따른 연방 및 주 세금 원천징수 의무를 충족하기 위한 필수 “sell-to-cover” 매도였습니다.
거래 후 Dulac는 직접적으로 106,062주 NTLA 주식을 보유하고 있으며, 간접 보유나 파생상품 변동은 보고되지 않았습니다. 옵션의 행사나 부여는 없었고, 추가적인 주식 매매도 공개되지 않았습니다.
이 사건은 경영진의 회사에 대한 경제적 노출에 실질적인 변화를 주지 않으며, 자발적 거래보다는 행정적 조치로 봐야 합니다.
Intellia Therapeutics, Inc. (NTLA) – Déclaration d’initié Formulaire 4
Le EVP et CFO Edward J. Dulac III a procédé à une vente automatique et non volontaire de 7 462 actions ordinaires le 23 juillet 2025 au prix de 14,02 $ par action. Cette cession était une vente obligatoire « sell-to-cover » visant à satisfaire les obligations de retenue d’impôt fédérales et étatiques déclenchées par l’acquisition des RSU le 22 juillet 2025.
Après la transaction, Dulac détient directement 106 062 actions NTLA ; aucune détention indirecte ni modification de titres dérivés n’a été signalée. Aucune option n’a été exercée ou attribuée, et la déclaration ne révèle aucune autre vente ou achat d’actions.
L’événement ne modifie pas de manière significative l’exposition économique de la direction à l’entreprise et doit être considéré comme une opération administrative plutôt que comme une transaction discrétionnaire.
Intellia Therapeutics, Inc. (NTLA) – Form 4 Insider-Meldung
EVP & CFO Edward J. Dulac III führte am 23. Juli 2025 einen automatischen, nicht freiwilligen Verkauf von 7.462 Stammaktien zum Preis von 14,02 $ pro Aktie durch. Die Veräußerung war ein verpflichtender „Sell-to-Cover“-Verkauf zur Erfüllung der bundesstaatlichen und staatlichen Steuerabzugsverpflichtungen, die durch die Vesting der RSUs am 22. Juli 2025 ausgelöst wurden.
Nach der Transaktion besitzt Dulac direkt 106.062 NTLA-Aktien; keine indirekten Beteiligungen oder Änderungen von Derivaten wurden gemeldet. Es wurden keine Optionen ausgeübt oder gewährt, und die Meldung enthält keine weiteren Aktienverkäufe oder -käufe.
Das Ereignis verändert die wirtschaftliche Beteiligung des Managements am Unternehmen nicht wesentlich und sollte als administrative und nicht als diskretionäre Handelsaktivität betrachtet werden.
SECURITIES AND EXCHANGE COMMISSION
The Securities Exchange Act of 1934
(Amendment No. )
SEPTEMBER 9, 2025
Secretary
July 25, 2025
| | |
Page
|
| |||
ABOUT THE MEETING
|
| | | | 1 | | |
HOUSEHOLDING OF ANNUAL MEETING MATERIALS
|
| | | | 6 | | |
PROPOSAL 1 — ELECTION OF DIRECTORS
|
| | | | 7 | | |
Director Qualifications
|
| | | | 7 | | |
Director Biographies
|
| | | | 8 | | |
Board Recommendation
|
| | | | 9 | | |
CORPORATE GOVERNANCE
|
| | | | 10 | | |
Board Leadership
|
| | | | 10 | | |
Code of Ethics
|
| | | | 10 | | |
Risk Oversight
|
| | | | 10 | | |
Director Independence
|
| | | | 10 | | |
Stock Ownership Guidelines
|
| | | | 11 | | |
Board of Directors and Committee Meetings
|
| | | | 11 | | |
Audit Committee
|
| | | | 11 | | |
Compensation Committee
|
| | | | 12 | | |
Nominating Committee
|
| | | | 12 | | |
Director Attendance at Annual Meetings
|
| | | | 13 | | |
Policy For Stockholder Communications
|
| | | | 13 | | |
Certain Relationships and Related Persons Transactions
|
| | | | 13 | | |
PROPOSAL 2 — RATIFICATION OF APPOINTMENT OF CBIZ CPAS P.C. AS THE
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR FISCAL 2026 |
| | | | 15 | | |
Board Recommendation
|
| | | | 16 | | |
AUDIT FEES
|
| | | | 17 | | |
Principal Accountant Fees and Services
|
| | | | 17 | | |
Audit Committee Pre-Approval
|
| | | | 17 | | |
AUDIT COMMITTEE REPORT
|
| | | | 18 | | |
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
| | | | 19 | | |
Delinquent Section 16 Reports
|
| | | | 20 | | |
Employee, Officer, Director Hedging Policy
|
| | | | 21 | | |
MANAGEMENT
|
| | | | 22 | | |
Officers of the Company
|
| | | | 22 | | |
EXECUTIVE COMPENSATION
|
| | | | 23 | | |
Compensation Discussion and Analysis
|
| | | | 23 | | |
Annual Bonuses
|
| | | | 26 | | |
Annual Incentive Plans
|
| | | | 27 | | |
Stock Ownership Guidelines
|
| | | | 28 | | |
Tax and Accounting Implications
|
| | | | 29 | | |
Compensation Committee Report
|
| | | | 29 | | |
Compensation Committee Interlocks and Insider Participation
|
| | | | 29 | | |
Compensation of NEOs
|
| | | | 29 | | |
SUMMARY COMPENSATION TABLE
|
| | | | 31 | | |
| | |
Page
|
| |||
OUTSTANDING EQUITY AWARDS AT FISCAL 2025 YEAR-END
|
| | | | 33 | | |
2019 Stock Incentive Plan
|
| | | | 33 | | |
OPTION EXERCISES AND STOCK VESTED IN FISCAL 2025
|
| | | | 34 | | |
Nonqualified Deferred Compensation
|
| | | | 34 | | |
Potential Payments Upon Termination or Change-in-Control
|
| | | | 34 | | |
Estimation of Benefits
|
| | | | 35 | | |
Risk Considerations in our Compensation Programs
|
| | | | 36 | | |
Equity Plan Information
|
| | | | 37 | | |
Pay Versus Performance
|
| | | | 37 | | |
Non-Employee Director Compensation
|
| | | | 40 | | |
2025 DIRECTOR COMPENSATION
|
| | | | 41 | | |
ANNUAL REPORT
|
| | | | 42 | | |
One Jericho Plaza
Jericho, New York 11753
Tuesday, September 9, 2025
One Jericho Plaza
Second Floor — Wing A
Jericho, New York 11753
Attention: Corporate Secretary
Name
|
| |
Age
|
| |
Principal Occupation
|
| |
Director
Since |
|
Robert J. Eide(1)(2)(3) | | |
72
|
| | Chairman and Chief Executive Officer – Aegis Capital Corp. | | |
1987
|
|
Eric Gatoff | | |
56
|
| | Chief Executive Officer – Nathan’s Famous, Inc. | | |
2005
|
|
Brian S. Genson(1)(2)(3)
|
| |
76
|
| | President – F1Collectors.com | | |
1999
|
|
Barry Leistner(1)(2) | | |
74
|
| | President and Chief Executive Officer – Koenig Iron Works, Inc. | | |
1989
|
|
Andrew M. Levine(3) | | |
70
|
| | Director of Real Estate, Fingerboard Family Office | | |
2020
|
|
Howard M. Lorber | | |
76
|
| | Executive Chairman of the Board – Nathan’s Famous, Inc. | | |
1987
|
|
Wayne Norbitz | | |
77
|
| |
Former President, Chief Operating Officer – Nathan’s Famous, Inc.
|
| |
1989
|
|
A. F. Petrocelli(3) | | |
81
|
| |
Former (Retired) Chief Executive Officer and Chairman of the
Board – United Capital Corp. |
| |
1993
|
|
Joanne Podell | | |
79
|
| |
Executive Vice Chairman For Retail Services, Cushman & Wakefield
|
| |
2023
|
|
Charles Raich(3) | | |
82
|
| |
Founding Partner (Retired) – Raich Ende Malter & Co., LLP
(acquired by Eisner Amper in 2022) |
| |
2004
|
|
| | |
2025
|
| |
2024
|
| ||||||
Audit Fees(1)
|
| | | $ | 397,000 | | | | | $ | 381,000 | | |
Audit-Related Fees(2)
|
| | | | 0 | | | | | | 0 | | |
Tax Fees(3)
|
| | | | 0 | | | | | | 0 | | |
All Other Fees(4)
|
| | | | 0 | | | | | | 0 | | |
Brian S. Genson
Barry Leistner
Name and Address(1)
|
| |
Amount and
Nature of Beneficial Ownership(2) |
| |
Percent of
Class* |
| ||||||
NEOs and Directors | | | | | | | | | | | | | |
Howard M. Lorber(3)(4)
|
| | | | 984,946 | | | | | | 24.1% | | |
Robert J. Eide(5)
|
| | | | 271,529 | | | | | | 6.6% | | |
Andrew M. Levine(6)
|
| | | | 263,750 | | | | | | 6.4% | | |
A. F. Petrocelli(7)
|
| | | | 53,750 | | | | | | 1.3% | | |
Eric Gatoff
|
| | | | 78,752 | | | | | | 1.9% | | |
Charles Raich(8)
|
| | | | 49,670 | | | | | | 1.2% | | |
Barry Leistner(9)
|
| | | | 40,159 | | | | | | 1.0% | | |
Brian S. Genson(10)
|
| | | | 10,792 | | | | | | ** | | |
Wayne Norbitz(11)
|
| | | | 3,750 | | | | | | ** | | |
Joanne Podell(12)
|
| | | | 6,250 | | | | | | ** | | |
Robert Steinberg
|
| | | | — | | | | | | — | | |
Directors and executive officers as a group (12 persons)
|
| | | | 1,264,211(13) | | | | | | 30.7% | | |
Principal Stockholders | | | | | | | | | | | | | |
GAMCO Investors, Inc. et al.(14)
|
| | | | 521,247 | | | | | | 12.7% | | |
Zilkha Partners Special Opportunities, L.P.(15) | | | | | | | | | | | | | |
Zilkha Partners, L.P.(9)
|
| | | | 247,674 | | | | | | 6.1% | | |
Name
|
| |
Age
|
| |
Position with the Company
|
|
Eric Gatoff | | |
56
|
| | Chief Executive Officer | |
Robert Steinberg | | |
56
|
| | Vice President Finance, Chief Financial Officer, Chief Accounting Officer, Treasurer and Secretary | |
Howard M. Lorber | | |
76
|
| | Executive Chairman of the Board | |
Leigh Platte* | | |
66
|
| | Senior Vice President, Food Service | |
Brian S. Genson
Barry Leistner
Name and Principal Position
|
| |
Year(1)
|
| |
Salary(1)
($) |
| |
Bonus
($) |
| |
Stock
Award(2) ($) |
| |
Option
Award ($) |
| |
Non-Equity
Incentive Plan Compensation(3) ($) |
| |
Change in
Pension Value and Nonqualified Deferred Compensation Earnings ($) |
| |
All Other
Compensation(4) ($) |
| |
Total
($) |
| |||||||||||||||||||||||||||
Eric Gatoff
Chief Executive Officer |
| | | | 2025 | | | | | $ | 625,000 | | | | | $ | 1,000,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 69,216 | | | | | $ | 1,694,216 | | |
| | | 2024 | | | | | $ | 637,019 | | | | | $ | 750,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 53,068 | | | | | $ | 1,440,087 | | | ||
| | | 2023 | | | | | $ | 602,668 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 1,200,000 | | | | | | — | | | | | $ | 41,704 | | | | | $ | 1,844,372 | | | ||
Robert Steinberg
Vice President – Finance, Chief Financial Officer, Treasurer and Secretary |
| | | | 2025 | | | | | $ | 325,000 | | | | | $ | 200,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 23,509 | | | | | $ | 548,509 | | |
| | | 2024 | | | | | $ | 229,327 | | | | | $ | 175,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 21,075 | | | | | $ | 425,402 | | | ||
| | | 2023 | | | | | $ | 220,534 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 150,000 | | | | | | — | | | | | $ | 32,499 | | | | | $ | 403,033 | | | ||
Howard M. Lorber
Executive Chairman of the Board |
| | | | 2025 | | | | | $ | 1,000,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 24,787 | | | | | $ | 1,024,787 | | |
| | | 2024 | | | | | $ | 1,000,000 | | | | | $ | 1,000,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 22,680 | | | | | $ | 2,022,680 | | | ||
| | | 2023 | | | | | $ | 1,000,000 | | | | | | — | | | | | $ | 3,379,500 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 15,942 | | | | | $ | 4,395,442 | | |
Name
|
| |
Company
Matched 401(k) Contributions ($)(1) |
| |
Insurance
Premiums ($)(2) |
| |
Mobile
Telephone Payments ($) |
| |
Auto
Allowance/Expense Reimbursement ($) |
| |
Total All Other
Compensation ($) |
| |||||||||||||||
Eric Gatoff
|
| | | $ | 2,287 | | | | | $ | 30,821 | | | | | $ | 2,689 | | | | | $ | 33,419 | | | | | $ | 69,216 | | |
Robert Steinberg
|
| | | $ | 2,475 | | | | | $ | 2,375 | | | | | $ | 0 | | | | | $ | 18,659 | | | | | $ | 23,509 | | |
Howard M. Lorber
|
| | | $ | 0 | | | | | $ | 787 | | | | | $ | 0 | | | | | $ | 24,000 | | | | | $ | 24,787 | | |
| | |
Option Awards
|
| |
Stock Award
|
| ||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares of Units of Stock That Have Not Vested(1) |
| |
Market
Value of Shares or Units of Stock That have Not Vested(2) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That have not Vested ($) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That have not Vested ($) |
| ||||||||||||||||||||||||
Eric Gatoff
Chief Executive Officer |
| | | | 0 | | | | | | 0 | | | | | $ | — | | | | | | — | | | | | | 0 | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Robert Steinberg
Vice President – Finance, Chief Financial Officer, Treasurer and Secretary |
| | | | 0 | | | | | | 0 | | | | | $ | — | | | | | | — | | | | | | 0 | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Howard M. Lorber
Executive Chairman of the Board |
| | | | 0 | | | | | | 0 | | | | | $ | — | | | | | | — | | | | | | 30,000 | | | | | $ | 2,844,000 | | | | | $ | — | | | | | $ | — | | |
| | |
Options Awarded
|
| |
Stock Awarded
|
| ||||||||||||||||||
| | |
Number of
Shares Acquired on Exercise (#) |
| |
Value
Realized on Exercise ($) |
| |
Number of
Shares Acquired on Vesting (#) |
| |
Value
Realized on Vesting ($) |
| ||||||||||||
Eric Gatoff
Chief Executive Officer |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Robert Steinberg
Vice President – Finance, Chief Financial Officer, Treasurer and Secretary |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Howard M. Lorber
Executive Chairman of the Board |
| | | | — | | | | | | — | | | | | | 10,000 | | | | | $ | 856,000 | | |
| | |
Termination
by Company without Cause or by Named Executive Officer with Good Reason |
| |
Death
|
| |
Termination
by Company of Named Executive Officer due to Disability |
| |
Termination
by Company for Cause or Voluntary Termination by Named Executive Officer Without Good Reason |
| |
Termination
by Company without Cause or by Named Executive Officer with Good Reason upon a Change in Control |
| |||||||||||||||
Cash Severance(1)
|
| | | $ | 507,692 | | | | | $ | 1,507,692 | | | | | $ | 1,507,692 | | | | | $ | 38,942 | | | | | $ | 1,663,942 | | |
Value of Accelerated Unvested Equity
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Benefits Continuation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | |
Termination
by Company without Cause |
| |
Death
|
| |
Termination
by Company of Named Executive Officer due to Disability |
| |
Termination
by Company for Cause or Voluntary Termination by Named Executive Officer |
| |
Termination
by Company without Cause or by Named Executive Officer upon a Change in Control |
| |||||||||||||||
Cash Severance(1)
|
| | | $ | 22,889 | | | | | $ | 22,889 | | | | | $ | 22,889 | | | | | $ | 22,889 | | | | | $ | 22,889 | | |
Value of Accelerated Unvested Equity
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | |
Termination
by Company without Cause or by Named Executive Officer with Good Reason |
| |
Death
|
| |
Termination
by Company of Named Executive Officer due to Disability |
| |
Termination
by Company for Cause or Voluntary Termination by Named Executive Officer Without Good Reason |
| |
Termination
by Company without Cause or by Named Executive Officer with Good Reason upon a Change in Control |
| |||||||||||||||
Cash Severance
|
| | | $ | 3,360,000 | | | | | $ | 3,333,333 | | | | | $ | 3,333,333 | | | | | $ | — | | | | | $ | 3,693,333 | | |
Value of Accelerated Unvested Equity
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 2,844,000 | | |
Benefits Continuation
|
| | | $ | 68,412 | | | | | $ | 74,361 | | | | | $ | 74,361 | | | | | | — | | | | | $ | 142,773 | | |
Excise Tax and Gross-Up
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Plan Category
|
| |
Number of securities
to be issued upon exercise of outstanding options (a) |
| |
Weighted-average
exercise price of outstanding options and warrants |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column a) |
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 130,000 | | | | | $ | 74.28 | | | | | | 38,584 | | |
Equity compensation plans not approved by security holders
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 130,000 | | | | | $ | 74.28 | | | | | | 38,584 | | |
Year | | | Summary Compensation Table Total For PEO | | | Compensation Actually Paid To PEO | | | Average Summary Compensation Table Total For Non- PEO NEOs(1) | | | Average Compensation Actually Paid To Non-PEOs(1)(2) | | | Value of Initial Fixed $100 Investment Based On Total Shareholder Return | | | Net Income | | ||||||||||||||||||
2025 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||
2024 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||
2023 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | |
| | | 2025 | | | 2024 | | | 2023 | | |||||||||||||||||||||||||||
Adjustments ($) | | | Eric Gatoff | | | Non-PEO NEOs* | | | Eric Gatoff | | | Non-PEO NEOs* | | | | | | Non-PEO NEOs* | | ||||||||||||||||||
SCT Amounts | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||
Adjustments for stock awards | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Aggregate value for stock awards included in “Stock Award” Column in SCT | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | |||||
Fair value at year-end of awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year-end | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||
Year-over-year change in fair value at covered fiscal year-end of awards granted in any prior fiscal year that were outstanding and unvested at the covered fiscal year-end | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | | | | | $ | | | |||||
Fair value at year-end of awards granted during the covered fiscal year-end that were vested at the covered fiscal year-end | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||
Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | | | | | $ | | | |||||
Dividends or other earnings paid on stock awards in the covered fiscal year prior to vesting if no otherwise included in the total compensation for the covered fiscal year | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||
Compensation Actually Paid (as calculated) | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | |
![[MISSING IMAGE: bc_netincome-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0000069733/000110465925070823/bc_netincome-4c.jpg)
![[MISSING IMAGE: bc_tsr-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0000069733/000110465925070823/bc_tsr-4c.jpg)
Name
|
| |
Fees
Earned or Paid in Cash ($) |
| |
Stock
Awards (%) |
| |
Option
Awards(1) ($) |
| |
Non-Equity
Incentive Plan Compensation ($) |
| |
Change in
Pension Value and Nonqualified Deferred Compensation Earnings ($) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| |||||||||
Robert J. Eide
|
| | | $ | 57,000 | | | | | | | | $ | 220,050 | | | | | | | | | | | | | | $ | 277,050 | | |
Brian S. Genson
|
| | | $ | 57,000 | | | | | | | | $ | 220,050 | | | | | | | | | | | | | | $ | 277,050 | | |
Barry Leistner
|
| | | $ | 54,000 | | | | | | | | $ | 220,050 | | | | | | | | | | | | | | $ | 274,050 | | |
Andrew Levine
|
| | | $ | 48,000 | | | | | | | | $ | 220,050 | | | | | | | | | | | | | | $ | 268,050 | | |
Wayne Norbitz
|
| | | $ | 47,000 | | | | | | | | $ | 220,050 | | | | | | | | | | | | | | $ | 267,050 | | |
A.F. Petrocelli
|
| | | $ | 47,000 | | | | | | | | $ | 220,050 | | | | | | | | | | | | | | $ | 267,050 | | |
Joanne Podell
|
| | | $ | 47,000 | | | | | | | | $ | 73,350 | | | | | | | | | | | | | | $ | 120,350 | | |
Charles Raich
|
| | | $ | 48,000 | | | | | | | | $ | 220,050 | | | | | | | | | | | | | | $ | 268,050 | | |
Name
|
| |
Outstanding
Stock Options |
| |||
Robert J. Eide
|
| | | | 15,000 | | |
Brian S. Genson
|
| | | | 15,000 | | |
Barry Leistner
|
| | | | 15,000 | | |
Andrew Levine
|
| | | | 25,000 | | |
Wayne Norbitz
|
| | | | 15,000 | | |
A.F. Petrocelli
|
| | | | 15,000 | | |
Joanne Podell
|
| | | | 15,000 | | |
Charles Raich
|
| | | | 15,000 | | |
Secretary
Jericho, New York
![[MISSING IMAGE: px_25nathanproxy1pg01-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0000069733/000110465925070823/px_25nathanproxy1pg01-bw.jpg)
![[MISSING IMAGE: px_25nathanproxy1pg02-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0000069733/000110465925070823/px_25nathanproxy1pg02-bw.jpg)